Showing results (261-270 of 282) with videos related to
Sort By:
Pageof 29
JCO Global Oncology|August 8, 2022
Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort StudyEloísa Riva, Patricio José Duarte, Bryan Valcárcel, et al.Blood Advances|June 5, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemiaAndrew R Branagan, Clifton Mo, Matthew Lei, et al.Leukemia & Lymphoma|July 3, 2018
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patientsArtur Jurczyszyn, Jorge J Castillo, Irit Avivi, et al.British Journal of Haematology|January 10, 2018
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patientsArtur Jurczyszyn, Jakub Radocha, Julio Davila, et al.Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2023
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.Blood|July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN StudyMeletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.American Journal of Hematology|April 7, 2017
IgM myeloma: A multicenter retrospective study of 134 patientsJorge J Castillo, Artur Jurczyszyn, Lucie Brozova, et al.JCO Global Oncology|July 16, 2021
Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de LinfoproliferativosLuis Malpica, Daniel J Enriquez, Denisse A Castro, et al.Pageof 29